PTC Therapeutics Raises 2026 Outlook as Q3 Revenue Hits $358 Million
PTC Therapeutics reported financial results for the third quarter ended September 30, 2026, on October 29, 2026, posting total revenues of $357.8 million and raising its full-year 2026 total revenue expectation to a range of $1.29 billion to $1.32 billion. The Warren, New Jersey-based company also disclosed that it acquired the ST-920 Fabry disease gene therapy from Sangamo Therapeutics during the quarter for $111.0 million upfront in cash. According to the company's third-quarter 2026 earnings…